Achieve Life Sciences, Inc.
NCM: ACHVLive Quote
About Achieve Life Sciences, Inc.
Healthcare
Biotechnology
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
📊 Fundamental Analysis
Achieve Life Sciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -257.7%, which indicates that capital utilization is currently under pressure.
At a current price of $3.49, ACHV currently sits at the 38th percentile of its 52-week range (Range: $1.95 - $6.03).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$574.89M
Trailing P/E
--
Forward P/E
-3.36
Beta (5Y)
1.96
52W High
$6.03
52W Low
$1.95
Avg Volume
653K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App